Seven cancer patients receiving guselkumab for treatment of moderate-to-severe psoriasis-Reference-Cited by-同舟云学术

Seven cancer patients receiving guselkumab for treatment of moderate-to-severe psoriasis

Published:2022-03-17 Issue:3 Volume:14 Page:
ISSN:2036-7406
Container-title:Dermatology Reports
language:
Short-container-title:Dermatol Reports

Author:

Mastorino Luca^ORCID,Siliquini Niccolò,Avallone Gianluca^ORCID,Ortoncelli Michela,Quaglino Pietro,Dapavo Paolo,Ribero Simone

Abstract

To the Editor: Limited evidence on the use of biologic treatments in psoriatic patients with a history of malignancy is currently available in the literature. The recently published European guidelines recommend the use of anti-TNF, anti-IL17, and anti-23 biological drugs in this special population after discussion case-by-case with a cancer-specialist [...].

Publisher

PAGEPress Publications

Subject

Dermatology

Reference7 articles.

1. Nast A, Smith C, Spuls PI et al. EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 2: specific clinical and comorbid situations. J Eur Acad Dermatol Venereol 2021;35:281-317.

2. Kahn JS, Casseres RG, Her MJ. Treatment of psoriasis with biologics and Apremilast in patients with a history of malignancy: a retrospective chart review. J Drugs Dermatol 2019;18.

3. Bellinato F, Gisondi P, Maurelli M, Girolomoni G. IL-17A inhibitors in patients with chronic plaque psoriasis and history of malignancy: A case series with systematic literature review. Dermatol Ther 2021;34:e14889.

4. Chyuan IT, Lai JH. New insights into the IL-12 and IL-23: From a molecular basis to clinical application in immune-mediated inflammation and cancers. Biochem Pharmacol 2020;175:113928.

5. Reich K, Armstrong AW, Foley P, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol 2017;76:418-31.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world outcomes in patients with malignancy and moderate-to-severe psoriasis treated with guselkumab;JAAD International;2024-09

2. A Multidisciplinary Approach to Patients with Psoriasis and a History of Malignancies or On-Treatment for Solid Tumors: A Narrative Literature Review;International Journal of Molecular Sciences;2023-12-16

3. A retrospective review of the management of patients following a malignancy diagnosis on biologic therapies for the treatment of dermatological disorders;JAAD Case Reports;2023-09

4. Psoriasis and skin cancer – Is there a link?;International Immunopharmacology;2023-08

5. The use of interleukin-23 inhibitors to treat immune-related psoriasis induced by immune checkpoint inhibitors and in patients with active cancer: A case series and review of the literature;SAGE Open Medical Case Reports;2023-01